A PD-L1 score for head and neck cancer helps guide treatment decisions, including when immunotherapy may be used. Here’s what your results mean.

Pfizer’s decision to cut its early-stage cancer asset was due to “strategic business reasons” and not driven by safety or ...

NORTHFIELD, Ill.--(BUSINESS WIRE)--The College of American Pathologists (CAP) in collaboration with the International Association for the Study of Lung Cancer (IASLC), Pulmonary Pathology Society (PPS ...

Association of HIPEC response in ovarian cancer with PI3K/RAS/Notch gene signatures: A whole transcriptomic analysis of U.S. and French HIPEC treated ovarian cancer patients. This is an ASCO Meeting ...

Recently in the Journal of Clinical Oncology, Monk et al 1 reported the final overall survival (OS) results of the KEYNOTE-826 study, which confirmed that pembrolizumab plus chemotherapy, with or ...

A new study published in the Journal of the National Cancer Institute brings researchers and oncologists one step closer to better understanding the complexities of PD-1 inhibitors, a common type of ...

A deep learning ‘pathomics’ model, Path-IO, showed higher accuracy than PD-L1 in predicting outcomes for metastatic non-small cell lung cancer patients on immunotherapy. Validated in international ...

Pfizer has abandoned work on a PD-L1-targeting drug that was being tested in patients with various cancers. | Pfizer has ...

Translational study in metastatic triple-negative breast cancer (mTNBC) shows leronlimab-mediated CCR5 inhibition induces PD-L1 expression, modulates immune checkpoint signaling, and is associated ...